Risk for heart failure events is decreased and health status is improved in patients with HFmrEF and HFpEF receiving finerenone.

Cardiovascular disease, sometimes abbreviated as CVD, is the leading cause of death worldwide. It’s a catchall term for heart ...

There’s no “silver bullet” for this problem, which is largely driven by clinical inertia, but some efforts are chipping away ...

A manufacturer-funded study found a significant decrease in annual total medical costs in patients with overweight/obesity ...

TX45 is being evaluated in the APEX phase 2 clinical trial (NCT06616974) in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). The trial is ...

Noninvasive liver fibrosis scores are associated with increased heart failure risk, with FIB-4, NFS, and APRI showing ...

Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression ...

Although finerenone has kidney protective effects in patients with chronic kidney disease and type 2 diabetes, it does not appear to slow kidney function decline in patients with heart failure with ...

Experimental Drug Engineered to Prevent Heart Failure After Heart Attacks Oct. 24, 2024 — An experimental therapeutic monoclonal antibody therapy could become the first to directly enhance ...

Results of Tenax Therapeutics’ Phase 2 HELP study of levosimendan in patients with pulmonary hypertension (PH) with heart failure with preserved ejection fraction (HFpEF) demonstrated that IV ...

in patients with Group 2 Pulmonary Hypertension in Heart Failure with Preserved Ejection Fraction (“PH-HFpEF”). The trial is designed to evaluate efficacy in the broad PH-HFpEF population and enrich ...